These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 8162658)

  • 21. Effects of the anticancer dehydrotarplatin on cytochrome P450 and antioxidant enzymes in male rat tissues.
    Nannelli A; Messina A; Marini S; Trasciatti S; Longo V; Gervasi PG
    Arch Toxicol; 2007 Jul; 81(7):479-87. PubMed ID: 17364183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted label-free approach for quantification of epoxide hydrolase and glutathione transferases in microsomes.
    Song W; Yu L; Peng Z
    Anal Biochem; 2015 Jun; 478():8-13. PubMed ID: 25769418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there more to learn about cytochrome P450 enzymes?
    Drug Ther Bull; 2014 May; 52(5):57-60. PubMed ID: 24832729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytochrome P450 genetic polymorphism in neonatal drug metabolism: role and practical consequences towards a new drug culture in neonatology.
    Fanni D; Ambu R; Gerosa C; Nemolato S; Castagnola M; Van Eyken P; Faa G; Fanos V
    Int J Immunopathol Pharmacol; 2014; 27(1):5-13. PubMed ID: 24674673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effects of CKD on Cytochrome P450-Mediated Drug Metabolism.
    Ladda MA; Goralski KB
    Adv Chronic Kidney Dis; 2016 Mar; 23(2):67-75. PubMed ID: 26979145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The pharmacokinetic process: is the drug getting to its site of action?: Drug metabolism].
    Carrillo Norte JA
    Rev Enferm; 2011; 34(7-8):52-60. PubMed ID: 21919387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes.
    Song Y; Li C; Liu G; Liu R; Chen Y; Li W; Cao Z; Zhao B; Lu C; Liu Y
    Clin Pharmacokinet; 2021 May; 60(5):585-601. PubMed ID: 33723723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro.
    Lübberstedt M; Müller-Vieira U; Mayer M; Biemel KM; Knöspel F; Knobeloch D; Nüssler AK; Gerlach JC; Zeilinger K
    J Pharmacol Toxicol Methods; 2011; 63(1):59-68. PubMed ID: 20460162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of hepatocytes to investigate UDP-glucuronosyltransferases and sulfotransferases.
    Fournel-Gigleux S; Coughtrie MW; Ouzzine M; Magdalou J
    Methods Mol Biol; 2010; 640():309-26. PubMed ID: 20645060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of Non-Cytochrome P450-Mediated Metabolism in Food and Drug Administration-Approved Oral and Intravenous Drugs: 2006-2015.
    Cerny MA
    Drug Metab Dispos; 2016 Aug; 44(8):1246-52. PubMed ID: 27084892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
    Cubitt HE; Houston JB; Galetin A
    Drug Metab Dispos; 2011 May; 39(5):864-73. PubMed ID: 21303923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease.
    Manns MP; Obermayer-Straub P
    Hepatology; 1997 Oct; 26(4):1054-66. PubMed ID: 9328334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of cytochromes P450 and phase II conjugation systems in precision-cut rat lung slices cultured up to 72 h.
    Umachandran M; Ioannides C
    Toxicology; 2006 Jul; 224(1-2):14-21. PubMed ID: 16701934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of immobilized enzymes in drug metabolism studies.
    Dulik DM; Fenselau C
    FASEB J; 1988 Apr; 2(7):2235-40. PubMed ID: 3127263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.
    Pirmohamed M; Madden S; Park BK
    Clin Pharmacokinet; 1996 Sep; 31(3):215-30. PubMed ID: 8877251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model compounds.
    Jyrkäs J; Lassila T; Tolonen A
    J Pharm Biomed Anal; 2023 Feb; 225():115219. PubMed ID: 36630767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review).
    Murray M
    Int J Mol Med; 1999 Mar; 3(3):227-38. PubMed ID: 10028046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biochemistry, physiology and drug metabolism--implications regarding the role of the lungs in drug disposition.
    Roth RA
    Clin Physiol Biochem; 1985; 3(2-3):66-79. PubMed ID: 3891197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children.
    Johnson TN
    Toxicology; 2003 Oct; 192(1):37-48. PubMed ID: 14511902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.